SpyGlass Pharma, Inc.

SpyGlass Pharma, Inc. is a U.S.-based ophthalmology company developing the BIM-IOL System, a drug-delivery platform designed for use in the eye. The company’s work centers on combining implantable ophthalmic technology with pharmaceutical treatment for glaucoma-related conditions, with development activities based in the United States.

12.67

12.67

— SpyGlass Pharma, Inc.
%
BIM-IOL System100% An investigational intraocular lens-based system designed to deliver drug therapy in the eye.

SpyGlass Pharma’s direct customers are not yet commercial buyers; its current focus is on clinical, regulatory, and...

  • Ophthalmologistsprimary

    Specialists who would prescribe or implant the BIM-IOL System for glaucoma-related treatment if approved.

  • Eye surgery centerssecondary

    Clinical settings where an implantable ophthalmic therapy would be administered or used.

  • Clinical trial investigatorsprimary

    Physicians and sites that run studies needed to generate safety and efficacy data.

  • Manufacturing and development partnersprimary

    Contract organizations that support formulation, manufacturing, and clinical operations.

The company is headquartered in the United States and its reported development activities are centered there...

  • •United States headquarters and operating base
  • •U.S. clinical and regulatory pathway is central to the program
  • •Future commercialization could expand into foreign ophthalmology markets
  • •International approval timing may differ from FDA timing

SpyGlass Pharma is focused on advancing the BIM-IOL System through clinical development, regulatory review, and...

01
Complete clinical development of the BIM-IOL Systemshort-term

Clinical data is required to support regulatory approval and future commercialization.

02
Build and defend intellectual propertyshort-term

Patent and trade secret protection are important to protect the platform from competitors.

03
Prepare for commercialization capabilitymedium-term

A successful approval would require manufacturing, sales, and distribution infrastructure.

SpyGlass Pharma is highly exposed to clinical, regulatory, and competitive risk because it has no approved products and...

high

Single-product concentration

The company is substantially dependent on the BIM-IOL System, so setbacks would materially affect the business.

Scope
Lead product candidate
Materiality
high
high

Clinical development failure

The product must demonstrate acceptable safety and efficacy in trials before approval.

Scope
Clinical trials
Materiality
high
high

Regulatory approval risk

FDA and foreign regulators may delay or deny approval, preventing commercialization.

Scope
FDA review
Materiality
high
high

Financing risk

The company expects to rely on external capital until it can generate product revenue.

Scope
Equity, debt, collaborations
Materiality
high
medium

Competitive pressure

Large ophthalmology and pharmaceutical companies may offer better or earlier alternatives.

Scope
Glaucoma therapies and ophthalmic devices
Materiality
high
medium

Intellectual property disputes

Patent challenges or infringement claims could delay development or weaken exclusivity.

Scope
Patents and trade secrets
Materiality
medium
Research and development accruals
Operating expense timing
Stock-based compensation
General and administrative and R&D expense
Fair value of short-term investments
Balance sheet and interest income
Emerging growth company disclosures
Financial statement comparability

SCYNEXIS INC

SCYX · Pharmaceutical Preparations

SOLIGENIX, INC.

SNGX · Pharmaceutical Preparations

Spyre Therapeutics, Inc.

SYRE · Pharmaceutical Preparations

ARROWHEAD PHARMACEUTICALS, INC.

ARWR · Pharmaceutical Preparations

Scilex Holding Co

SCLX · Biological Products, (No Diagnostic Substances)

IONIS PHARMACEUTICALS INC

IONS · Pharmaceutical Preparations

: 16.6.2026